- May 6, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Orilissa
Synonyms :
elagolix
Class :
Gonadotropin-releasing hormone antagonists
Dosage Forms & Strengths
Tablet
150mg
200mg
Safety and efficacy not established
It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism
elagolix: they may diminish the therapeutic effect of hormonal contraceptives
elagolix: they may diminish the therapeutic effect of hormonal contraceptives
elagolix: they may diminish the therapeutic effect of hormonal contraceptives
elagolix: they may diminish the therapeutic effect of hormonal contraceptives
may enhance the serum concentration of CYP3A4 inhibitors
may increase the levels of serum concentration of elagolix
may increase the levels of serum concentration of elagolix
may increase the levels of serum concentration of elagolix
may increase the levels of serum concentration of elagolix
may increase the levels of serum concentration of elagolix
may increase the serum concentration of elagolix
OATP1B1/1B3 inhibitors increase the concentration of elagolix in the serum
OATP1B1/1B3 inhibitors increase the concentration of elagolix in the serum
OATP1B1/1B3 inhibitors increase the concentration of elagolix in the serum
OATP1B1/1B3 inhibitors increase the concentration of elagolix in the serum
OATP1B1/1B3 inhibitors increase the concentration of elagolix in the serum
It may diminish the effect when combined with pemigatinib by affecting CYP3A4 metabolism
It may diminish the effect when combined with lumateperone by affecting CYP3A4 metabolism
the level of effect of lenvatinib will increase by MDR1 P-glycoprotein efflux transporter due to elagolix
CYP3A strong enhancers of the small intestine may reduce the bioavailability of elagolix
OATP1B1/1B3 inhibitors increase the concentration of elagolix in serum
may enhance the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors
may enhance the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors
may enhance the serum concentration of OATP1B1/1B3 (SLCO1B1/1B3) Inhibitors
indium In-111 capromab pendetide
may decrease the diagnostic effect when combined
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may increase the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
It may enhance the metabolism when combined with dexamethasone
It may enhance the effect when combined with irinotecan liposomal by P-glycoprotein efflux
It may diminish the levels when combined with tamsulosin by affecting CYP3A4 metabolism
when both drugs are combined, there may be an increased level of serum concentration of etoposide
when both drugs are combined, there may be a reduced metabolism of paclitaxel
when both drugs are combined, there may be a decreased metabolism of elagolix
it increases brentuximab vedotin level with the help of (MDR1) P-glycoprotein efflux transporter.
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
the effect of elagolix is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
elagolix decreases the effect of ixazomib by altering intestinal/hepatic CYP3A4 enzyme metabolism
may reduce therapeutic effects of docetaxel by inducing hepatic metabolism enzyme CYP3A4
may reduce therapeutic effects of erdafitinib by inducing hepatic metabolism enzyme CYP3A4
fedratinib increases the effect of elagolix by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
elagolix decreases the effect or level of pexidartinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporter
it enhances by affecting the P-Glycoprotein (MDR1) efflux transporter
may decrease the level by affecting hepatic enzyme CYP3A4 metabolism
it increases by affecting the hepatic enzyme CYP3A4 metabolism
hormonal contraceptives decrease the efficacy of elagolix
Adverse drug reactions
Frequency Defined
>10%
Nausea
Headache
1-10%
Amenorrhea (4-7%)
Arthralgia (3-5%)
Insomnia (6-9%)
Hypersensitivity reactions (5.8%)
Mood altered, mood swings (5-6%)
Depressed mood (3-6%)
Anxiety (3-5%)
≥3%-<5%
Abdominal pain
Weight gain
Dizziness
Constipation
Decreased libido
Diarrhea
Irritability
Pregnancy warnings:
US FDA pregnancy category: Not Assigned
Lactation:
Excreted into human milk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: elagolix
Why do we use elagolix?
elagolix is a Gonadotropin Releasing Hormone Antagonists used to treat Endometriosis.
ADVERTISEMENT
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
USA – BOSTON
60 Roberts Drive, Suite 313
North Adams, MA 01247
INDIA – PUNE
7, Shree Krishna, 2nd Floor, Opp Kiosk Koffee, Shirole Lane, Off FC Road, Pune 411004, Maharashtra
Founded in 2014, medtigo is committed to providing high-quality, friendly physicians, transparent pricing, and a focus on building relationships and a lifestyle brand for medical professionals nationwide.
MASSACHUSETTS – USA
60 Roberts Drive, Suite 313,
North Adams, MA 01247
MAHARASHTRA – INDIA
7, Shree Krishna, 2nd Floor,
Opp Kiosk Koffee,
Shirole Lane, Off FC Road,
Pune 411004, Maharashtra
